Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETI crossover trial in cystic fibrosis with rare non-F508del mutations
ACTRN12623001136695Phase 4Completed
- Sponsor
- The University of Newcastle
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by The University of Newcastle. Primary endpoint: Primary: absolute difference in ppFEV1. Started Nov 2023; status: completed.
02
Drugs
elexacaftor + tezacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on ACTRN12623001136695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001136695.